Extrait

The primary objective of this study is to confirm the long-term safety and tolerability of canakinumab 150 mg subcutaneously (s.c) compared to triamcinolone acetonide 40 mg intramuscularly (i.m).

Critère d'inclusion

• Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective

Liens

• ictrp
• euctr